Best Ophthalmology Companies in China
The 44 best Ophthalmology companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Frontera Therapeutics.
- Growth Foreseen for Ophthalmology Sector
Ranked: Best Ophthalmology companies in China
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EyeDeal Developing medical devices for ophthalmology | — | — | Unfunded | Guangxu Guo Founder & CEO | — | — | — | — |
| 2 | Gaush Provider of ophthalmic medical devices, equipment, instruments, and related consumables | — | — | Public | — | 821 | NginxSwiperjQuery+3 | — | — |
| 3 | Guangzhou Ruitai Biotechnology Developer of regenerative repair materials and related medical device products | — | — | Funding Raised | Hao Xu Founder | — | — | — | — |
| 4 | iCamumo Developer of cell therapies for multiple diseases | — | — | Funding Raised | Liu Xiaodong Founder | 80 | — | — | 2 job openings |
| 5 | IPAC Pharma Developer of therapeutics to treat ophthalmic diseases | — | — | Unfunded | DAMON BURROWS Co-Founder | — | — | — | — |
| 6 | Jiangsu Wanxin Optical Company Manufacturer of ophthalmic lenses. The company is engaged in the design, manufacture and sale of ophthalmic… | — | — | Acquired | — | 2,000 | — | — | — |
| 7 | Mofajing Developer of a smart glasses designed to help teenagers correct eye vision. | — | — | Private | — | 8 | — | — | — |
| 8 | OcuMension Developer of ophthalmic drugs | — | — | Public | — | 417 | — | — | — |
Top 12 Ophthalmology companies in China
#1
Series B · Wuhan, Hubei · founded 2017$40Mraised▾
Developer of cell therapies to treat neurological and ophthalmological diseases. The company focuses on the development of a new generation of chemically induced cell therapy products, for untreatable diseases, such as Parkinson's disease and blindness. The company's product pipeline includes NN001 and NN002 for neurological disorders, NS001, and NS001 for diabetic neuropathy and optic neuropathy.
- Sep 2025Series B$40M
- Aug 2021Series A—
- Jul 2020Seed—
- Jan 2019Seed—
#2
Series D · Beijing, Beijing · founded 2017 · 240 employees$70.5Mraised▾
Developer of OCT and optical biometers for ophthalmic diseases. It offers devices which include endoscopic OCT, microscope, ultra-wide-field fundus camera, and others for diagnosis of ophthalmic disorders.
- Jul 2024Series D$27.5M
- Dec 2022Series D$43M
#3
Seed · Hong Kong, Hong Kong · founded 2021$10Mraised▾
Provider of gene editing-based solutions for genetic diseases. The company develops precision gene-editing technology and develop a pipeline of programmable gene therapy products.
- Sep 2024Seed—
- Apr 2024Seed$10M
#4
Series C · Wuhan, Hubei · founded 2016 · 76 employees$125Mraised▾
Developer of drugs for retina-related diseases. By using the AAV gene therapy platform the company has developed drugs for ophthalmic diseases. The product pipeline includes NFS-01 for Leber hereditary optic neuropathy, NFS-04 for glaucoma, NFS-05 for Dominant hereditary optic atrophy, and NFS-10 for vascular retinopathy.
- Aug 2023Series C—
- Apr 2022Series C—
- Nov 2021Series C$63M
- Feb 2021Series B$62M
#5
Series E · Pudong, Shanghai · founded 2016$46Mraised▾
Developer of therapeutic solutions for treating multiple eye diseases. The company has developed a drug candidate VVN001 that helps in treating dry eye diseases such as e dryness, foreign body sensation, burning, itching, photophobia, jealousy, and blurred vision. Other products include VVN349 for atopic dermatitis, VVN460 for psoriasis, VVN539 for glaucoma, and many more.
- Dec 2023Series E—
- Apr 2021Series D$46M
#6
Series B · Suzhou, Jiangsu · founded 2019 · 65 employees$90Mraised▾
Developer of therapeutics for ocular disorders. It offers a pipeline of drug candidates EB-101 for wet AMD, EB-102 for diabetic macular edema, EB-105 for retinal vascular diseases, EB-108 for wet AMD, and others.
- Feb 2023Series B$40M
- Nov 2020Series A$50M
#7
Series B · Suzhou, Jiangsu · founded 2019 · 41 employees$195Mraised▾
Developer of AAV-based gene therapies for the treatment of rare and chronic diseases. The company focuses on developing recombinant AVV products for the treatment of genetic disorders including those of ophthalmology, liver, metabolic, and neuromuscular diseases.
- Jun 2022Series B$160M
#8
Series A · Suzhou, Jiangsu · founded 2015$8.5Mraised▾
Provider of ophthalmology diagnosis and analysis systems. The company has developed a multi-platform (Windows, Linux, Mac OS) ophthalmic imaging computer-aided and analysis software MIPA, which integrates disease diagnosis and analysis, disease growth prediction, efficacy evaluation, and others. The software is based on ophthalmic-image processing algorithms.
- May 2024Series A$4.1M
- Dec 2021Series A—
- Sep 2018Series A$4.4M
#9
Series A · Jinshan, Shanghai · founded 2017$21.1Mraised▾
Provider of smart eye protection solutions for children and teenagers to prevent myopia. Itoffer innovative technologies and solutions in the field of eye care.
- Aug 2023Series A$13.9M
- Dec 2022Series A$7.2M
#10
Series A · Suzhou, Jiangsu · founded 2018 · 9 employees$25Mraised▾
Developer of drugs for neurological disorders. It offers pipeline candidates which include FB-1071 for amyotrophic lateral sclerosis, FB-1005 for stroke, FB1001 for glaucoma, FB1003 for pain, and FB1004 for Alzheimer's disease.
- Dec 2022Series A$14M
- Feb 2021Series A—
#11
Public · Yantai, Shandong · founded 2008 · 3591 employees$100Mraised▾
Remegen is a developer of therapies for the treatment of cancer, autoimmune and eye diseases. Its technology is based on antibody and fusion proteins, antibody-drug conjugates (ADCs), and bifunctional antibodies therapies. The platform has developed drug candidate R18 that is the fusion protein for the rheumatoid arthritis treatment.
- Mar 2020PE$100M
#12
Series B · Shanghai, Shanghai · founded 2017 · 18 employees$15.4Mraised▾
Developer of nano-antibody drugs for multiple ailments. The company has developed a portfolio of products to treat cancers, ophthalmic disorders, immune disorders, and others. They have developed technologies including a phage-displayed nanobody library, cell line development platform, cell line process development, and antibody activity analysis platform to develop nano-antibodies.
- Mar 2021Series B$15.4M
- May 2019Series B—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Ophthalmology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Medical Devices is moving in China
A read on the academic research around Medical Devices — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,507 China-affiliated papers.
- Beijing Institute of Technology92
- Harbin Institute of Technology72
- Chinese Academy of Sciences65
- National Medical Products Administration59
- Peking University58
- Surgical robot34→82
- Robot36→81
- Surgical instrument1→23
- Medical robotics3→11
- Biocompatible material1→7
- Surgical robot81→143
- Robot80→132
- Medical robotics4→16
- Drug delivery1→12
- Key (lock)4→12
- Surgical robot2→34
- Robot3→33
- Field (mathematics)2→10
- Robotics1→9
- Nanotechnology2→7
Where medical devices is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing medical devices patents in China
China medical devices patent filing is accelerating — 55,767 filings from 8,000 assignees (2016–2025), led by Shanghai United Imaging Healthca, Shenzhen Mindray Biomedical Elec, Huawei TECH; annual filings 2339→7886.
- Shanghai United Imaging Healthca2213
- Shenzhen Mindray Biomedical Elec1416
- Huawei TECH1203
- BOE Technology Group1071
- UNIV Tsinghua764
- Lifetech Scient Shenzhen745
- Medtrum TECH612
- Nuctech574
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.